Personalis, Inc. (NASDAQ:PSNL) Sees Large Increase in Short Interest

Personalis, Inc. (NASDAQ:PSNL) saw a significant increase in short interest in February. As of February 13th, there was short interest totaling 10,685,978 shares, an increase of 21.2% from the January 29th total of 8,813,216 shares. Based on an average daily trading volume, of 1,248,699 shares, the short-interest ratio is currently 8.6 days. Approximately 12.5% of the company’s shares are sold short. Approximately 12.5% of the company’s shares are sold short. Based on an average daily trading volume, of 1,248,699 shares, the short-interest ratio is currently 8.6 days.

Personalis Price Performance

PSNL opened at $8.67 on Wednesday. The firm has a market cap of $907.14 million, a PE ratio of -9.53 and a beta of 2.02. The stock has a 50-day moving average price of $8.84 and a 200-day moving average price of $8.06. Personalis has a 1 year low of $2.83 and a 1 year high of $11.50.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.05. The company had revenue of $17.35 million for the quarter, compared to the consensus estimate of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 42.81%. As a group, sell-side analysts anticipate that Personalis will post -1.4 EPS for the current year.

Institutional Trading of Personalis

Several institutional investors have recently added to or reduced their stakes in PSNL. Caitong International Asset Management Co. Ltd increased its holdings in shares of Personalis by 76.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after buying an additional 7,896,714 shares during the last quarter. Oracle Investment Management Inc. increased its holdings in Personalis by 47.9% in the 4th quarter. Oracle Investment Management Inc. now owns 339,343 shares of the company’s stock worth $2,701,000 after buying an additional 109,908 shares in the last quarter. First Manhattan CO. LLC. purchased a new position in Personalis in the 4th quarter worth about $2,976,000. Finally, Guggenheim Capital LLC purchased a new position in Personalis in the 4th quarter worth about $108,000. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on PSNL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a report on Saturday. Morgan Stanley boosted their target price on shares of Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a report on Monday, December 1st. HC Wainwright upped their target price on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Finally, BTIG Research lifted their price target on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Personalis has a consensus rating of “Moderate Buy” and an average price target of $11.14.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.